Norvax® Minova 4WD


Diseases Treated


Inactivated vaccine against furunculosis, coldwater vibriosis, vibriosis and wound disease for intraperitoneal injection in Atlantic salmon.

Inactivated strains of Listonella (Vibrio) anguillarum serovar O1, Listonella (Vibrio) anguillarum serovar O2α, Aeromonas salmonicida subsp. salmonicida, Vibrio salmonicida and Moritella viscosa.

Emulsion for injection.

For active immunization of Atlantic salmon to reduce mortality due to the diseases furunculosis caused by Aeromonas salmonicida subsp. salmonicida, vibriosis caused by Listonella (Vibrio) anguillarum serovar O1 and/or Listonella (Vibrio) anguillarum serovar O2α, coldwater vibriosis caused by Vibrio salmonicida and wound disease caused by Moritella viscosa.

Inject 0.1 ml intraperitoneally along the central line, 1 - 1.5 fin lengths in front of the pelvic fin base. Ensure the recommended dose is deposited into the abdominal cavity before the needle is withdrawn. The length and diameter of the needle should be adapted to the actual fish size.

Nil. (National regulations should be observed).

Norvax® Minova 4WD is available in 500-ml PET bottles.

Store and transport between 2 and 8°C. Do not freeze. Opened bottles should be used within 4 hours. Don't use after the expiry date.


Vaccination is recommended for fish at or above 35 grams. The water temperature at vaccination should be at or below 15°C. Fish should be withheld from feed for 1-2 days before vaccination. Fish should be anaesthetised according to veterinary recommendations. Start feeding, at the earliest, 12 hours after vaccination. Only healthy fish should be vaccinated. Do not use in breeding stock. No information is available on the safety and efficacy from the concurrent use of this vaccine with any other. It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination with this product. Shake well before use. Sterile injection equipment should be used. At least 500 degree days are recommended from vaccination to potential exposure to furunculosis, vibriosis, coldwater vibriosis and wound disease.

When undesirable effects occur, they are normally seen in the abdominal cavity. Vaccinated animals normally show very slight to moderate adhesions between viscera or between viscera and the abdominal wall. The eventual adhesions may be removed manually and are thus not severe. Occasionally, vaccinated populations may show adhesions between greater parts of the abdominal organs, granulomas and/or more massive pigmentation. Such lesions are typically seen in < 10% of the treated animals.